-4.60% to $142.77 from $149.66
What moved MRNA
- Moderna announced a private placement of $2.0 billion in convertible senior notes due 2032, plus up to $300 million in initial purchaser options, sparking investor concern over potential share dilution and expanded long-term liabilities.
- Separately, the FDA approved supplemental Biologics License Applications for the 2026-2027 formulas of Spikevax and mNEXSPIKE.
- The notes offering follows a sharp rise in Moderna shares earlier in the month after Phase 3 mRNA cancer vaccine data from its collaboration with Merck.
Sources: TradingKey · Barchart
+176.97% to $174.38 from $62.96
What moved MRNA
- The Phase 3 INTerpath-001 trial enrolled 1,137 patients with surgically removed high-risk melanoma, testing the personalized vaccine (intismeran autogene) plus Merck’s Keytruda against Keytruda alone.
- The trial met its primary goal of reducing cancer recurrence and its secondary goal of preventing the cancer from spreading to other parts of the body.
- It marks the first positive Phase 3 result ever recorded for an individualized neoantigen therapy and for any mRNA-based cancer treatment.
- Earlier-stage data on the same combination had shown a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death versus Keytruda alone.
- The companies plan to begin discussions with regulators over the coming months about the treatment’s approval pathway.
- Moderna’s rally also lifted other vaccine and biotech peers, including Novavax and BioNTech.
Sources: CNBC · STAT News · Reuters
+9.86% to $59.17 from $53.86
What moved MRNA
- The FDA approved Moderna’s mFlusiva, the first flu vaccine made using mRNA technology, for adults age 50 and older.
- The agency granted standard approval for ages 50-64 and accelerated approval for those 65 and older, contingent on a postmarketing study spanning two flu seasons.
- In a late-stage trial, the vaccine was found to be about 27% more effective than a standard flu shot, with no new safety signals identified.
- Moderna expects mFlusiva to be available in the U.S. for the 2026-2027 flu season.
Sources: STAT News · MedCity News · NBC News · NPR
-4.26% to $53.86 from $56.26
What moved MRNA
- The FDA approved Moderna’s mFLUSIVA, the first mRNA-based influenza vaccine in the U.S., for adults 50 years and older.
- Approval for the 65-and-older age group is conditional on Moderna conducting an additional clinical trial.
- In trials the vaccine was about 27% more effective than a standard flu shot, and Moderna said it will be available this fall.
Sources: BioSpace · AJMC